Core One Labs Inc. (CLABF) Income Statement Analysis

See more : Lacto Japan Co., Ltd. (3139.T) Income Statement Analysis – Financial Results

Complete financial analysis of Core One Labs Inc. (CLABF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Core One Labs Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

ATRenew Inc. (RERE) Income Statement Analysis – Financial Results
Landmark Property Development Company Limited (LPDC.BO) Income Statement Analysis – Financial Results
Connected IO Limited (CIO.AX) Income Statement Analysis – Financial Results
Sandbridge Acquisition Corporation (SBG) Income Statement Analysis – Financial Results
Deutsche Telekom AG (DTEGY) Income Statement Analysis – Financial Results

Core One Labs Inc. (CLABF)

Industry: Biotechnology

Sector: Healthcare

Website: https://core1labs.com

About Core One Labs Inc.

Core One Labs Inc. operates as a biotechnology research and technology life sciences company. The company focuses on bringing psychedelic medicines to market through novel delivery systems, psychedelic assisted psychotherapy, and API grade psilocybin manufacturing. Its CannaStrips technology produces infused strips that allow for bioavailability of cannabis constituents. The company also offers consulting, financing, and micro cultivation services, as well as operates medical and wellness clinics. In addition, it provides natural health products; and news dissemination services. The company was formerly known as Lifestyle Delivery Systems Inc. and changed its name to Core One Labs Inc. in September 2019. Core One Labs Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	458.54K	431.62K	0.00	5.04M	4.08M	191.13K	56.09K	58.30K	0.00	0.00	0.00	0.00
Cost of Revenue	42.20K	38.77K	0.00	5.71M	5.77M	0.00	0.00	1.60K	0.00	0.00	0.00	0.00
Gross Profit	416.34K	392.85K	0.00	-669.57K	-1.69M	191.13K	56.09K	56.70K	0.00	0.00	0.00	0.00
Gross Profit Ratio	90.80%	91.02%	0.00%	-13.28%	-41.40%	100.00%	100.00%	97.26%	0.00%	0.00%	0.00%	0.00%
Research & Development	80.34K	627.29K	97.91K	1.12M	1.12M	2.71M	65.08K	59.06K	0.00	0.00	0.00	0.00
General & Administrative	0.00	8.36M	5.47M	8.13M	7.77M	8.67M	1.63M	920.79K	304.70K	328.25K	459.34K	260.27K
Selling & Marketing	0.00	3.71M	1.03M	1.42M	1.29M	1.78M	112.87K	8.77K	15.00K	0.00	0.00	0.00
SG&A	8.17M	12.07M	6.50M	9.56M	9.06M	10.44M	1.74M	929.56K	319.70K	328.25K	459.34K	260.27K
Other Expenses	0.00	37.30K	614.95K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	8.25M	12.64M	7.14M	14.67M	10.24M	13.16M	2.00M	1.11M	430.17K	328.25K	459.34K	260.27K
Cost & Expenses	8.30M	12.64M	7.14M	20.38M	16.01M	13.16M	2.00M	1.11M	430.17K	328.25K	459.34K	260.27K
Interest Income	0.00	0.00	0.00	0.00	4.34K	12.65K	0.00	752.00	2.07K	2.57K	109.00	51.00
Interest Expense	1.37K	22.25K	16.47K	575.41K	130.29K	32.65K	0.00	20.01K	0.00	0.00	0.00	0.00
Depreciation & Amortization	42.20K	38.77K	206.30K	6.09M	54.74K	6.92K	187.56K	121.51K	110.47K	279.94K	0.00	0.00
EBITDA	-7.80M	-12.13M	-6.52M	-9.25M	-11.87M	-12.97M	-1.75M	-931.17K	-319.70K	-212.13K	-459.34K	-260.27K
EBITDA Ratio	-1,699.99%	-2,811.50%	0.00%	-183.52%	-290.79%	-6,786.39%	-3,125.56%	-1,597.26%	0.00%	0.00%	0.00%	0.00%
Operating Income	-7.84M	-12.17M	-6.52M	-15.34M	-11.92M	-12.98M	-1.94M	-1.07M	-430.17K	-492.07K	-459.34K	-260.27K
Operating Income Ratio	-1,709.20%	-2,820.48%	0.00%	-304.24%	-292.13%	-6,790.01%	-3,459.98%	-1,841.30%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	-8.14M	-24.82M	-39.75M	-5.74M	-1.10M	-154.02K	-925.78K	-133.99K	2.07K	-116.12K	109.00	0.00
Income Before Tax	-15.98M	-37.05M	-46.90M	-21.65M	-13.15M	-13.16M	-2.87M	-1.21M	-428.10K	-441.80K	-459.23K	0.00
Income Before Tax Ratio	-3,485.36%	-8,585.16%	0.00%	-429.47%	-322.33%	-6,887.69%	-5,110.62%	-2,069.84%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	3.00	59.55K	7.71M	386.16K	-736.22K	-535.24K	0.00	20.01K	0.00	-166.39K	0.00	260.22K
Net Income	-15.98M	-37.05M	-54.62M	-21.46M	-12.29M	-12.60M	-2.87M	-1.21M	-428.10K	-441.80K	-459.23K	-260.22K
Net Income Ratio	-3,485.36%	-8,585.16%	0.00%	-425.72%	-301.09%	-6,590.56%	-5,110.62%	-2,069.84%	0.00%	0.00%	0.00%	0.00%
EPS	-0.49	-2.57	-10.27	-15.25	-10.56	-17.52	-8.71	-7.79	-12.06	-14.11	-14.76	-10.65
EPS Diluted	-0.49	-2.57	-10.27	-15.25	-10.56	-17.52	-8.71	-7.79	-12.06	-14.11	-14.76	-10.65
Weighted Avg Shares Out	32.71M	14.42M	5.32M	1.41M	1.16M	718.83K	328.95K	154.82K	35.50K	31.32K	31.11K	24.42K
Weighted Avg Shares Out (Dil)	32.71M	14.42M	5.32M	1.41M	1.16M	718.83K	328.95K	154.82K	35.50K	31.32K	31.11K	24.42K

Core One Labs Provides Clarification on Trading Activity

May 21, 2021accesswire.com

VANCOUVER, BC / ACCESSWIRE / May 21, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62, WKN:A2P8K3) (the "Company" or "Core One"). This news release is issued at the request of the Investment Industry Regulatory Organization of Canada ("IIROC") and the...

Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer's Disease

May 6, 2021globenewswire.com

VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has...

World Renowned Physician Joins Core One Labs as Chief Medical Officer

May 5, 2021globenewswire.com

VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce it has appointed Dr. Santiago Ferro, Chief Executive Officer of...

Core One Labs Unaware of Any Material Change that Would Account for Significant Share Price Depreciation

May 4, 2021accesswire.com

VANCOUVER, BC / ACCESSWIRE / May 4, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the "Company" or "Core One") wishes to confirm that management is unaware of any material change in the Company's operations that would account...

Core One Labs Completes Milestone Acquisition of Akome Biotech

May 4, 2021globenewswire.com

VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to...

Core One Labs Appoints Patent Expert, Dr. Dan Polonenko, To Advisory Board

April 29, 2021accesswire.com

VANCOUVER, BC / ACCESSWIRE / April 29, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) (the "Company") is pleased to announce it has appointed Dr. Dan Polonenko to its Advisory Board, effective immediately. Dr. Polonenko has also agreed to consult...

Core One Labs Reaches Definitive Agreement to Acquire Akome Biotech

April 29, 2021globenewswire.com

VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”), a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased...

REPEAT -- Core One Labs to Explore Joint Venture with Lobe Sciences for the Clinical Development of Biosynthetic Psilocybin

April 28, 2021globenewswire.com

VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce it has entered into a letter of intent, dated April 27,...